Compare CABO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABO | IMCR |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.1M | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | CABO | IMCR |
|---|---|---|
| Price | $133.64 | $36.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $126.00 | $67.00 |
| AVG Volume (30 Days) | 147.0K | ★ 338.1K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,524,897,000.00 | $379,590,000.00 |
| Revenue This Year | N/A | $32.31 |
| Revenue Next Year | N/A | $10.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 28.11 |
| 52 Week Low | $96.67 | $23.15 |
| 52 Week High | $390.25 | $40.72 |
| Indicator | CABO | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 49.05 |
| Support Level | $119.44 | $35.35 |
| Resistance Level | $128.95 | $40.71 |
| Average True Range (ATR) | 6.61 | 1.82 |
| MACD | 3.79 | -0.45 |
| Stochastic Oscillator | 87.37 | 22.55 |
Cable One Inc. is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. From a product standpoint, the majority of revenue comes from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols. Cable One Inc. owns its telecommunications infrastructure.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.